0000899243-20-009607.txt : 20200326
0000899243-20-009607.hdr.sgml : 20200326
20200326210141
ACCESSION NUMBER: 0000899243-20-009607
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200324
FILED AS OF DATE: 20200326
DATE AS OF CHANGE: 20200326
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: TOMBESI PAOLO
CENTRAL INDEX KEY: 0001707648
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35945
FILM NUMBER: 20747675
MAIL ADDRESS:
STREET 1: 10 FINDERNE AVENUE
STREET 2: BUILDING 10
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Epizyme, Inc.
CENTRAL INDEX KEY: 0001571498
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 261349956
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 TECHNOLOGY SQUARE
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-229-5872
MAIL ADDRESS:
STREET 1: 400 TECHNOLOGY SQUARE
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-03-24
0
0001571498
Epizyme, Inc.
EPZM
0001707648
TOMBESI PAOLO
C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE
CAMBRIDGE
MA
02139
0
1
0
0
Chief Financial Officer
Common Stock, par value $0.0001
2020-03-24
4
A
0
1690
A
16680
D
Common Stock, par value $0.0001
2020-03-25
4
S
0
1243
15.28
D
15437
D
Represents common stock issued upon vesting of restricted stock units granted under the issuer's 2013 Stock Incentive Plan that vested upon the issuer's achievement of a specified performance target. The transaction date represents the date on which the issuer's Compensation Committee determined that the performance target was achieved.
Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the restricted stock units described in footnote 1. The automatic sale of the reporting person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person.
/s/ John Weidenbruch, attorney-in-fact
2020-03-26